Gordon Findlay, the Healthcare Executive of Novo Nordisk, fainted Thursday at the Oval Office during a weight loss drug announcement. The event focused on GLP-1 medications was temporarily paused as attention shifted to Findlay.
"During the Most Favored Nations Oval Office Announcement, a representative with one of the companies fainted," said White House Press Secretary Karoline Leavitt. "The White House Medical Unit quickly jumped into action, and the gentleman is okay. The Press Conference will resume shortly."
The announcement featured President Donald Trump, Dr. Mehmet Oz, and other speakers as they introduced a deal with Eli Lilly and Novo Nordisk. The agreement aims to offer certain obesity drugs to Americans at approximately $150 per month.
During Eli Lilly CEO David Ricks' speech, Findlay lost consciousness, prompting staff to evacuate the press and Dr. Kennedy to fetch medical help. The press conference resumed at 1:29 p.m. without further incidents, according to White House Deputy Press Secretary Kush Desai.
Summary: During a White House event on affordable weight loss drugs, Novo Nordisk executive Gordon Findlay fainted but quickly recovered, causing a brief pause before the conference resumed.